Holen Sie sich die Stockscreener-App
12.97
1.14%
-0.15
Vorhandelsmarkt:
13.01
0.04
+0.31%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Piper Sandler raises Viatris stock price target to $12 on brand strength By Investing.com - Investing.com India
Piper Sandler raises Viatris stock price target to $12 on brand strength - Investing.com
Should Viatris’ (VTRS) First Inpefa UAE Launch Shape Investor Views on Its Innovation Strategy? - simplywall.st
Understanding the Setup: (VTRS) and Scalable Risk - Stock Traders Daily
Will Viatris Inc benefit from green energy policiesPortfolio Value Report & Free Verified High Yield Trade Plans - baoquankhu1.vn
Viatris Launches Inpefa In UAE As Valuation And Growth Draw Focus - Sahm
Is Viatris (VTRS) Pricing Reflect Its Recent Multi‑Year Share Price Recovery - Yahoo Finance
Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch - Yahoo Finance
Viatris Earnings Preview: What to Expect - Barchart.com
Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com Nigeria
Viatris launches heart failure drug Inpefa in UAE, first outside US By Investing.com - Investing.com South Africa
3 Reasons to Sell VTRS and 1 Stock to Buy Instead - Finviz
Viatris Inc. Stock Outperforms Market Despite Losses On The Day - 富途牛牛
Viatris Launches Inpefa in United Arab Emirates - marketscreener.com
Viatris Launches Inpefa To Treat Heart Failure In UAE - Nasdaq
Viatris Launches Inpefa, Expanding Its Heart Failure Portfolio And Broadening Presence In Cardiovascular Diseases - TradingView — Track All Markets
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - PR Newswire
Movement Recap: Is Viatris Inc backed by strong institutional buyingBear Alert & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy - Construction World India
Levels Update: Will Viatris Inc stock hit new highs in YEARJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Argus Research Upgrades Viatris (VTRS) - Nasdaq
Biocon Secures Rs 4,150 Cr Through QIP to Buy Out Viatris Stake in Biologics Arm - Medical Dialogues
Viatris stock tests multi-year ceiling after impressive rally - FXStreet
United States Treatment-Resistant Depression Market to grow - openPR.com
Cash offers target up to $450M of Viatris 2026 and 2025 notes - Stock Titan
Viatris (VTRS) Gets a Sell from Bank of America Securities - The Globe and Mail
Biocon Raises Rs 4,150 Cr via QIP Issue - Rediff MoneyWiz
RSI Check: Is Viatris Inc. impacted by rising ratesWeekly Profit Summary & Daily Profit Focused Screening - baoquankhu1.vn
Contact UsCeres CourierViatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation - FinancialContent
Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next - TechStock²
Generic Drugs Market to Hit US$ 942.69 Billion by 2033 | CAGR 7.1% | - openPR.com
Viatris Inc. stock rises Tuesday, outperforms market - MSN
What is the earnings history of Viatris IncWeekly Investment Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Viatris Stock: Is Wall Street Bullish or Bearish? - MSN
Viatris hits main goals in Phase 3 trial for birth control patch - MSN
Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims - Law360
Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛
Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target - Yahoo Finance
Viatris Inc.: Can a Hybrid Pharma Powerhouse Reinvent the Generic Drug Game? - AD HOC NEWS
Goldman Sachs Adjusts Price Target on Viatris to $13 From $12, Maintains Neutral Rating - marketscreener.com
Can Viatris Inc. stock deliver strong Q4 earningsTrend Reversal & Growth Focused Entry Point Reports - ulpravda.ru
How analysts revise price targets for Viatris Inc. (VIA) stockCPI Data & High Conviction Investment Ideas - ulpravda.ru
Does Viatris Inc. (VIA) stock trade below intrinsic value2025 Historical Comparison & Real-Time Volume Trigger Notifications - ulpravda.ru
Viatris Inc. Stock Rises Thursday, Outperforms Market - 富途牛牛
Performance Recap: Why Viatris Inc. stock remains on buy listsMarket Activity Report & Safe Entry Zone Identification - ulpravda.ru
Viatris names veteran executive to lead people and corporate affairs - The Business Journals
Viatris stock hits 52-week high at 12.68 USD By Investing.com - Investing.com South Africa
Viatris stock hits 52-week high at 12.68 USD - Investing.com
Why Viatris Inc. stock remains on buy listsEarnings Trend Report & AI Powered Trade Plan Recommendations - ulpravda.ru
Viatris appoints Lara Ramsburg as chief people and corporate affairs officer - marketscreener.com
Viatris names Lara Ramsburg as chief people and corporate affairs officer - Investing.com Australia
Viatris names Lara Ramsburg as chief people and corporate affairs officer By Investing.com - Investing.com South Africa
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer - Viatris
Viatris Inc.: How a Quiet Generic Drug Giant Is Re?wiring Global Healthcare - AD HOC NEWS
Barclays initiates Viatris (VTRS) with overweight as pharma sentiment improves - MSN
Is Viatris stock outperforming the Dow? - MSN
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
0.75%
2.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):